Asian Competitors Teach Swiss Pharma Manufacturers a Lesson

Swiss pharmaceutical manufacturers, long a global powerhouse, are facing intensified competition from Asian rivals. South Korea's Samsung Biologics is making a significant move by attempting to acquire Baar-based peptide maker Polypeptide for nearly 1.5 billion Swiss francs.

This acquisition signals a broader trend of Asian companies, including those from China and India, aggressively expanding into the high-value pharmaceutical sector. While Switzerland remains a top-tier location for pharmaceutical innovation and production, with companies like Roche and Novartis, its competitive edge is being challenged. Market observers rank Switzerland, alongside Denmark, third in competitiveness, trailing the United States and Ireland.

Samsung Biologics' rapid ascent, fueled by substantial investments in large-scale production facilities in South Korea, exemplifies this shift. The company has become a major player in contract manufacturing for pharmaceutical giants. Polypeptide, a specialist in peptide production, a crucial component for weight-loss drugs, represents a particularly attractive target in a rapidly expanding market.

Lonza, a Swiss competitor, previously divested its peptide manufacturing division to Polypeptide in 2017. Now, with Polypeptide's international production sites in Sweden, France, the US, and India, Samsung's potential acquisition would not only grant it access to the lucrative peptide market but also significantly expand its global manufacturing footprint.

“

The example shows that Asian companies are also pursuing ambitious growth plans in drug production.